Elekta (OTCMKTS:EKTAY) Reaches New 12-Month High – Still a Buy?

Elekta AB (OTCMKTS:EKTAY) reached a new 52-week high during trading on Thursday . The company traded as high as $6.32 and last traded at $6.32, with a volume of 435 shares trading hands. The stock had previously closed at $6.2750.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised Elekta from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Elekta Price Performance

The company has a quick ratio of 0.79, a current ratio of 1.04 and a debt-to-equity ratio of 0.66. The stock has a fifty day moving average of $5.49 and a two-hundred day moving average of $5.19. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of 90.30 and a beta of 1.04.

Elekta (OTCMKTS:EKTAY) last posted its quarterly earnings results on Wednesday, November 26th. The company reported $0.07 earnings per share for the quarter. Elekta had a net margin of 1.62% and a return on equity of 12.14%. The business had revenue of $427.85 million for the quarter, compared to analysts’ expectations of $436.91 million. On average, equities research analysts anticipate that Elekta AB will post 0.36 earnings per share for the current year.

About Elekta

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.